Lysosome-Dependent Sphingolipid Regulation as a potential therapeutic Target for Cohen Syndrome

This study identifies cationic amphiphilic drugs that restore Golgi morphology and neurite outgrowth in Cohen Syndrome models by correcting VPS13B deficiency-induced sphingolipid imbalances, suggesting a novel lysosome-dependent therapeutic strategy for the disorder.

The Gist

The Problem: A Broken Factory in the Brain

Imagine your body is a massive city, and every cell is a factory. Inside these factories, there is a crucial department called the Golgi complex. Think of the Golgi as the post office and shipping center. Its job is to take packages (proteins and lipids), sort them, label them, and ship them to the right place so the cell can function and grow.

Cohen Syndrome is a rare genetic disease caused by a broken instruction manual (a mutation in the VPS13B gene). In people with this syndrome, the "shipping center" (the Golgi) falls apart. Instead of being one organized building, it shatters into tiny, useless fragments.

Because the shipping center is broken, the factory can't send out the right supplies. This causes major problems, especially in the brain. Children with Cohen Syndrome often have smaller brains (microcephaly) and struggle with development because their brain cells can't grow long "wires" (neurites) to talk to each other. Currently, there is no cure for the brain-related symptoms.

The Detective Work: Finding a Fix

The scientists in this paper wanted to find a way to glue the broken shipping center back together. They couldn't just fix the broken gene easily, so they tried a different approach: trial and error with a massive toolbox.

1. The Test: They created a model of the broken factory using lab-grown cells.
2. The Search: They tested over 1,200 different drugs (many of which are already approved for other things like allergies or depression) to see if any of them could make the shattered Golgi look normal again.
3. The Surprise: They found about 50 drugs that worked! But here's the twist: these drugs didn't work by fixing the broken gene directly.

The "Magic Trick": The Janitor Analogy

Most of the successful drugs belong to a group called Cationic Amphiphilic Drugs (CADs). These are drugs that have a special chemical property: they love to get stuck inside the cell's "trash cans" (lysosomes).

Here is the analogy:
Imagine the Golgi (shipping center) is broken because the trash cans (lysosomes) are clogged with garbage, or perhaps because the trash cans are too clean and empty.

When these specific drugs enter the cell, they act like sticky janitors. They get trapped in the lysosomes and cause a buildup of lipids (fats). It sounds bad, right? Usually, too much fat in the trash can is a disease (like Niemann-Pick disease).

But in this specific case, the scientists discovered a weird side effect: The "clogged" trash cans actually sent a signal that helped rebuild the broken shipping center.

It's like if you jammed a wrench into a broken conveyor belt, the vibration accidentally realigned the gears, and the belt started working again. The drugs didn't fix the cause of the break; they created a new environment that forced the cell to reorganize its shipping center.

The Key Ingredient: The "C18" Lipid

The scientists dug deeper to understand why this worked. They found that in the broken cells, a specific type of fat called C18 Sphingolipid was missing.

Think of C18 lipids as the special glue needed to hold the shipping center together. In Cohen Syndrome, the factory runs out of this glue.

• The "sticky janitor" drugs (the CADs) caused the cell to hoard fats.
• This hoarding somehow tricked the cell into making more of that missing C18 glue.
• With the glue restored, the shipping center (Golgi) snapped back together.

Testing on "Mini-Brains"

To make sure this wasn't just a trick that worked in a petri dish, the scientists tested two of the drugs (Azelastine and Raloxifene) on brain organoids.

• What is a brain organoid? Imagine growing a tiny, 3D model of a human brain in a dish. It's like a "mini-brain" that mimics how a real baby's brain develops.
• The Result: The mini-brains from Cohen Syndrome patients were small and their neurons (brain cells) were short and stubby, unable to reach out and connect.
• The Fix: When the scientists added the drugs, the neurons grew longer and reached out to connect with each other! The drugs didn't make the mini-brains huge, but they fixed the "wiring" problem.

The Big Picture

This paper is a story of scientific serendipity.

1. They looked for a drug to fix a broken shipping center.
2. They found drugs that usually cause "fat storage" (which is usually bad).
3. They discovered that this fat storage actually restored the missing "glue" (C18 lipids) needed to fix the shipping center.
4. They proved it works in complex brain models.

Why does this matter?
It suggests that we might be able to treat Cohen Syndrome (and potentially other brain development disorders) by using existing, cheap drugs that we already know are safe. We don't need to invent a new drug from scratch; we just need to repurpose these "sticky janitors" to help the brain's shipping center get back to work.

In short: The scientists found that by accidentally clogging the cell's trash cans with specific drugs, they accidentally fixed the brain's broken shipping center, allowing brain cells to grow and connect again.

Technical Summary

1. Problem Statement

Cohen Syndrome (CS) is a rare autosomal recessive disorder caused by biallelic mutations in the VPS13B gene (also known as COH1). It affects approximately 50,000 individuals worldwide and presents with multisystemic symptoms, including postnatal microcephaly, intellectual disability, neutropenia, and progressive retinal dystrophy.

• Cellular Phenotype: Loss of VPS13B, a Bridge-like Lipid Transfer Protein (BLTP), leads to the fragmentation of the Golgi complex, a consistent cellular defect observed in CS models.
• Therapeutic Gap: While metabolic and immunological symptoms are manageable, there are currently no therapies to prevent or mitigate the central nervous system (CNS) manifestations (e.g., microcephaly) of CS. The precise molecular mechanism linking VPS13B loss to Golgi fragmentation and neuronal defects remains unclear, hindering target-based drug discovery.

2. Methodology

The authors employed a multi-pronged approach combining high-throughput phenotypic screening, lipidomics, and advanced disease modeling:

• Cellular Model: Generated VPS13B knockout (KO) HeLa cell clones using CRISPR-Cas9. These clones exhibited confirmed Golgi fragmentation (visualized via GM130 and GOLPH3 staining).
• High-Content Screening (HCS): Screened the Prestwick Chemical Library (PCL) (1,280 FDA/EMA-approved drugs) using a microscopy-based assay. The readout was the restoration of Golgi morphology (measuring fragment area, perimeter, shape factor, and count per cell) in VPS13B KO cells.
• Mechanistic Investigation:
  • Lipidomics: Performed LC-MS/MS lipid profiling to identify specific lipid alterations in VPS13B KO cells.
  • Genetic Validation: Silenced genes associated with lysosomal storage diseases (LSDs), specifically NPC1 (Niemann-Pick C) and SMPD1 (Niemann-Pick A/B), to test if induced lipid storage mimics the drug effect.
  • Subcellular Fractionation: Separated light (endo-lysosomal) and heavy (ER/Golgi) membrane fractions to determine the localization of lipid changes.
  • Enzymatic Inhibition: Used inhibitors of Ceramide Synthase (FB1) and Ceramide Transfer Protein (HPA-12) to distinguish between lipid accumulation due to storage vs. increased synthesis.
• Physiological Relevance: Tested lead compounds in human cortical organoids (COs) derived from VPS13B KO human pluripotent stem cells (hPSCs), a model recapitulating secondary microcephaly and impaired neurite outgrowth.

3. Key Contributions & Results

A. Identification of Cationic Amphiphilic Drugs (CADs)

The screen identified 50 compounds capable of restoring Golgi morphology in VPS13B KO cells.

• Common Mechanism: The vast majority of hits (47/50) are Cationic Amphiphilic Drugs (CADs). These molecules possess a basic amine (pKa > 7) and high hydrophobicity (LogP > 3.5), causing them to accumulate in acidic organelles (lysosomes/endosomes).
• Lysosomal Lipid Storage: Treatment with these CADs (e.g., azelastine, dilazep, trifluoperazine, raloxifene) induced a dose-dependent accumulation of lipids (LBPA, cholesterol, phospholipids) in lysosomes, phenocopying genetic LSDs.
• Genetic Confirmation: Silencing NPC1 or SMPD1 in VPS13B KO cells also restored Golgi morphology, confirming that lysosomal lipid accumulation is the mechanism rescuing the Golgi defect, rather than a direct interaction with VPS13B.

B. Lipidomic Profiling: The C18 Sphingolipid Defect

Lipidomic analysis revealed a specific metabolic signature in VPS13B KO cells:

• Deficit: A significant reduction (20–30%) in C18-N-acyl sphingolipids, specifically SM 36:1 (C18 sphingomyelin) and CER 36:1 (C18 ceramide).
• Significance: C18 SM is known to bind and regulate TMED proteins, which are crucial for Golgi-ER trafficking. Its depletion likely contributes to Golgi fragmentation.
• Drug Correction: CAD treatment reversed this specific deficit. While CADs caused a general accumulation of lipids in lysosomes, they specifically restored C18 SM and CER levels in the heavy membrane fraction (containing ER/Golgi) to near wild-type levels.
• Synthesis vs. Storage: The increase in C18 sphingolipids was not blocked by synthesis inhibitors (FB1, HPA-12), suggesting the restoration is due to a metabolic regulation or reduced turnover of these specific species in the context of lysosomal storage, rather than de novo synthesis.

C. Specificity and Toxicity

• Specificity: CADs did not prevent Golgi fragmentation induced by Brefeldin A (BFA) or Nocodazole, nor did they accelerate recovery from these agents. However, they reversed Golgi dispersion caused by Statins (which inhibit prenylation), indicating the rescue is specific to the CS/Golgi integrity pathway.
• Organoid Validation:
  • Neurite Outgrowth: Treatment with azelastine and raloxifene significantly restored neurite outgrowth in primary neurons dissociated from VPS13B KO organoids.
  • Organoid Size: While neurite outgrowth was rescued, long-term treatment (30 days) of intact organoids did not significantly recover the reduced organoid size (microcephaly phenotype), likely due to toxicity at effective concentrations or the complexity of the developmental defect.

4. Significance and Implications

• Novel Therapeutic Mechanism: This study proposes a "phenotypic rescue" strategy where lysosomotropic drugs (CADs) are repurposed to correct Golgi defects in CS. The mechanism involves the induction of lysosomal lipid storage, which paradoxically restores the levels of specific C18 sphingolipids required for Golgi integrity.
• Bridging Lipidomics and Neurodevelopment: The work links a specific lipid deficit (C18 sphingolipids) to the neurodevelopmental pathology of Cohen Syndrome, providing a molecular rationale for the observed microcephaly and neuronal defects.
• Drug Repurposing Potential: Several identified compounds (e.g., azelastine, an antihistamine; raloxifene, a SERM) are already FDA-approved. This opens the door for rapid clinical translation, provided safety profiles in the CNS can be established.
• Paradigm Shift: The findings challenge the view of lysosomotropic drugs solely as toxic side-effect inducers (phospholipidosis), suggesting they can be therapeutic agents for specific genetic disorders involving lipid trafficking and organelle morphology.

Conclusion

The authors demonstrate that Cationic Amphiphilic Drugs (CADs) can rescue the Golgi fragmentation and neurite outgrowth defects in Cohen Syndrome models. This rescue is mediated by the induction of lysosomal lipid storage, which specifically corrects the deficiency of C18 sphingolipids. While long-term organoid size recovery remains a challenge, the restoration of neuronal morphology highlights a promising, mechanism-based therapeutic avenue for a currently untreatable genetic disorder.